Christopher Johnson, MD
Family Medicine · Rogers, ARNPI 1508824871
Payments from drug & device makers
Across 234 payments — averaging $14.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$788
- Lilly USA, LLC$396
- AbbVie$383
- Novo Nordisk$288
- Amgen$288
- GSK$246
- plus $1K from 25 others
What the payments were for
- Food & beverage$3,391100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 55 | $788 |
| Lilly USA, LLC | 32 | $396 |
| AbbVie(2 entities) | 21 | $383 |
| Novo Nordisk | 23 | $288 |
| Amgen | 18 | $288 |
| GSK | 19 | $246 |
| Astellas Pharma US Inc | 7 | $111 |
| Dynavax Technologies Corporation | 7 | $106 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 5 | $81 |
| Abbott | 5 | $70 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $63 |
| Supernus Pharmaceuticals, Inc. | 4 | $61 |
| Bayer | 3 | $50 |
| Exact Sciences | 3 | $47 |
| Ironshore Pharmaceuticals Inc. | 2 | $40 |
| Phathom Pharmaceuticals, Inc. | 3 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $35 |
| Sanofi Pasteur Inc. | 2 | $35 |
| Organon | 2 | $32 |
| Exeltis, USA Inc. | 2 | $31 |
| Biohaven Pharmaceuticals, Inc. | 2 | $27 |
| AstraZeneca | 2 | $25 |
| Merck | 2 | $24 |
| Dexcom, Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Teva Pharmaceuticals USA, Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Biogen | 1 | $16 |
| Boehringer Ingelheim | 1 | $15 |
| Johnson & Johnson | 1 | $13 |
| Mylan Pharmaceuticals Inc. | 1 | $12 |
How this compares
$3,391 in reported general payments places this provider in the 80th percentile of 1,347 family medicine providers in Arkansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 136 | $187,806 |
| EliquisApixaban | 128 | $107,418 |
| FarxigaDapagliflozin Propanediol | 69 | $85,091 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 54 | $64,592 |
| XareltoRivaroxaban | 65 | $64,108 |
| JardianceEmpagliflozin | 25 | $39,797 |
| MyrbetriqMirabegron | 17 | $21,782 |
| JanuviaSitagliptin Phosphate | 30 | $21,166 |
| LinzessLinaclotide | 23 | $19,812 |
| Breo ElliptaFluticasone/Vilanterol | 15 | $13,131 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 23 | $11,790 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $8,265 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 23 | $7,657 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 47 | $6,289 |
| Rivastigmine | 32 | $5,787 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $288 | $187,806136 claims |
| PfizerEliquis | $788 | $107,418128 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $25 | $98,603102 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $246 | $89,51492 claims |
| Johnson & JohnsonXarelto | $13 | $64,10865 claims |
| Boehringer IngelheimJardiance | $15 | $39,79725 claims |
| Astellas Pharma US IncMyrbetriq | $111 | $21,78217 claims |
| MerckJanuvia | $24 | $21,16630 claims |
| AbbVieLinzess | $383 | $19,81223 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,347 family medicine providers in Arkansas.
Other family medicine in Rogers
- John SmileyRogers$13K
- George KonisLittle Rock$26.6M
- Kevin RobertsLittle Rock$2.5M
- Derek LewisLittle Rock$1.7M
- Jodi SansonHot Springs$1.7M
- Senthil RaghavanLittle Rock$496K
- Broderick EatonWynne$442K
- Landon HumphreyConway$417K
- Vonda HouchinHarrisburg$206K
- Glenn GibbonsFort Smith$179K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.